Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination

Vaccine

Volumn 29, Issue 24, 2011, Pages 4142-4150

  Chovancova, Zita ^a   Vlkova, Marcela ^a   Litzman, Jiri ^a   Lokaj, Jindrich ^a   Thon, Vojtech ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

CVID; ELISPOT; Pneumococcal vaccine; Tetanus toxoid

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCZYME;

ADULT; AGED; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BLOOD; CELL DIFFERENTIATION; CELL SUBPOPULATION; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; MALE; PLASMA CELL; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, BACTERIAL; B-LYMPHOCYTES; CELL DIFFERENTIATION; COMMON VARIABLE IMMUNODEFICIENCY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; TETANUS TOXOID;

EID: 79956128949     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.087     Document Type: Article

References (58)

1. Conley M.E., Notarangelo L.D., Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999, 93:190-197.
2. Chapel H., Lucas M., Lee M., Bjorkander J., Webster D., Grimbacher B., et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008, 112:277-286.
3. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999, 92:34-48.
4. Rakhmanov M., Keller B., Gutenberger S., Foerster C., Hoenig M., Driessen G., et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci U S A 2009, 106:13451-13456.
5. Piqueras B., Lavenu-Bombled C., Galicier L., Bergeron-van der Cruyssen F., Mouthon L., Chevret S., et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol 2003, 23:385-400.
6. Warnatz K., Denz A., Drager R., Braun M., Groth C., Wolff-Vorbeck G., et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 2002, 99:1544-1551.
7. Taubenheim N., von Hornung M., Durandy A., Warnatz K., Corcoran L., Peter H.H., et al. Defined blocks in terminal plasma cell differentiation of common variable immunodeficiency patients. J Immunol 2005, 175:5498-5503.
8. Ferry B.L., Jones J., Bateman E.A., Woodham N., Warnatz K., Schlesier M., et al. Measurement of peripheral B cell subpopulations in common variable immunodeficiency (CVID) using a whole blood method. Clin Exp Immunol 2005, 140:532-539.
9. Litzman J., Vlkova M., Pikulova Z., Stikarovska D., Lokaj J. T and B lymphocyte subpopulations and activation/differentiation markers in patients with selective IgA deficiency. Clin Exp Immunol 2007, 147:249-254.
10. Thon V., Wolf H.M., Sasgary M., Litzman J., Samstag A., Hauber I., et al. Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients. Clin Exp Immunol 1997, 110:174-181.
11. Funauchi M., Farrant J., Moreno C., Webster A.D. Defects in antigen-driven lymphocyte responses in common variable immunodeficiency (CVID) are due to a reduction in the number of antigen-specific CD4+ T cells. Clin Exp Immunol 1995, 101:82-88.
12. Fischer M.B., Hauber I., Eggenbauer H., Thon V., Vogel E., Schaffer E., et al. A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency. Blood 1994, 84:4234-4241.
13. Giovannetti A., Pierdominici M., Mazzetta F., Marziali M., Renzi C., Mileo A.M., et al. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol 2007, 178:3932-3943.
14. Bryant A., Calver N.C., Toubi E., Webster A.D., Farrant J. Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2. Clin Immunol Immunopathol 1990, 56:239-248.
15. Fischer M.B., Hauber I., Wolf H.M., Vogel E., Mannhalter J.W., Eibl M.M. Impaired TCR signal transduction, but normal antigen presentation, in a patient with common variable immunodeficiency. Br J Haematol 1994, 88:520-526.
16. Farrington M., Grosmaire L.S., Nonoyama S., Fischer S.H., Hollenbaugh D., Ledbetter J.A., et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A 1994, 91:1099-1103.
17. Horn J., Manguiat A., Berglund L.J., Knerr V., Tahami F., Grimbacher B., et al. Decrease in phenotypic regulatory T cells in subsets of patients with common variable immunodeficiency. Clin Exp Immunol 2009, 156:446-454.
18. Mouillot G., Carmagnat M., Gérard L., Garnier J.L., Fieschi C., Vince N., et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol 2010, 30(5):746-755.
19. van Zelm M.C., Reisli I., van der Burg M., Castaño D., van Noesel C.J., van Tol M.J., et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006, 354:1901-1912.
20. Salzer U., Maul-Pavicic A., Cunningham-Rundles C., Urschel S., Belohradsky B.H., Litzman J., et al. ICOS deficiency in patients with common variable immunodeficiency. Clin Immunol 2004, 113:234-240.
21. Grimbacher B., Hutloff A., Schlesier M., Glocker E., Warnatz K., Dräger R., et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003, 4:261-268.
22. van Zelm M.C., Smet J., Adams B., Mascart F., Schandené L., Janssen F., et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010, 120(4):1265-1274.
23. Sekine H., Ferreira R.C., Pan-Hammarström Q., Graham R.R., Ziemba B., de Vries S.S., et al. Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A 2007, 104:7193-7198.
24. Castigli E., Wilson S.A., Garibyan L., Rachid R., Bonilla F., Schneider L., et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005, 37:829-834.
25. Salzer U., Chapel H.M., Webster A.D., Pan-Hammarström Q., Schmitt-Graeff A., Schlesier M., et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005, 37:820-828.
26. Mohammadi J., Liu C., Aghamohammadi A., Bergbreiter A., Du L., Lu J., et al. Novel mutations in TACI (TNFRSF13B) causing common variable immunodeficiency. J Clin Immunol 2009, 29:777-785.
27. Schaffer A.A., Salzer U., Hammarstrom L., Grimbacher B. Deconstructing common variable immunodeficiency by genetic analysis. Curr Opin Genet Dev 2007, 17:201-212.
28. Wehr C., Kivioja T., Schmitt C., Ferry B., Witte T., Eren E., et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008, 111:77-85.
29. Goldacker S., Draeger R., Warnatz K., Huzly D., Salzer U., Thiel J., et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007, 124:294-303.
30. Rezaei N., Aghamohammadi A., Siadat S.D., Moin M., Pourpak Z., Nejati M., et al. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin Vaccine Immunol 2008, 15:607-611.
31. Rezaei N., Siadat S.D., Aghamohammadi A., Moin M., Pourpak Z., Norouzian D., et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiency. Clin Vaccine Immunol 2010, 17:524-528.
32. Seidel M.G., Grohmann E., Sadeghi K., Pollak A., Heitger A., Forster-Waldl E. Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy. Vaccine 2010, 28:6621-6626.
33. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983, 65:109-121.
34. Thomson S.P., McMahon L.J., Nugent C.A. Endogenous cortisol: a regulator of the number of lymphocytes in peripheral blood. Clin Immunol Immunopathol 1980, 17:506-514.
35. Bertouch J.V., Roberts-Thomson P.J., Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. Br Med J (Clin Res Ed) 1983, 286:1171-1172.
36. Stevens R.H., Macy E., Morrow C., Saxon A. Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization. J Immunol 1979, 122:2498-2504.
37. Kodo H., Gale R.P., Saxon A. Antibody synthesis by bone marrow cells in vitro following primary and booster tetanus toxoid immunization in humans. J Clin Invest 1984, 73:1377-1384.
38. Thiele C.J., Morrow C.D., Stevens R.H. Human IgA antibody and immunoglobulin production after in vivo tetanus toxoid immunization: size and surface membrane phenotype analysis. J Clin Immunol 1982, 2:327-334.
39. Cunningham-Rundles C., Bodian C., Ochs H.D., Martin S., Reiter-Wong M., Zhuo Z. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol 2001, 100:181-190.
40. Ochs H.D., Davis S.D., Wedgwood R.J. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest 1971, 50:2559-2568.
41. Rezaei N., Aghamohammadi A., Read R.C. Response to polysaccharide vaccination amongst pediatric patients with common variable immunodeficiency correlates with clinical disease. Iran J Allergy Asthma Immunol 2008, 7:231-234.
42. Alachkar H., Taubenheim N., Haeney M.R., Durandy A., Arkwright P.D. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 2006, 120:310-318.
43. Klein U., Kuppers R., Rajewsky K. Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 1997, 89:1288-1298.
44. Shi Y., Agematsu K., Ochs H.D., Sugane K. Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol 2003, 108:128-137.
45. Tangye S.G., Tarlinton D.M. Memory B cells: effectors of long-lived immune responses. Eur J Immunol 2009, 39:2065-2075.
46. Weller S., Braun M.C., Tan B.K., Rosenwald A., Cordier C., Conley M.E., et al. Human blood IgM " memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004, 104:3647-3654.
47. Sanchez-Ramon S., Radigan L., Yu J.E., Bard S., Cunningham-Rundles C. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol 2008, 128:314-321.
48. Warnatz K., Schlesier M. Flowcytometric phenotyping of common variable immunodeficiency. Cytometry B Clin Cytom 2008, 74:261-271.
49. Carsetti R., Rosado M.M., Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004, 197:179-191.
50. Pinna D., Corti D., Jarrossay D., Sallusto F., Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol 2009, 39:1260-1270.
51. Agenes F., Rosado M.M., Freitas A.A. Peripheral B cell survival. Cell Mol Life Sci 2000, 57:1220-1228.
52. Viallard J.F., Blanco P., André M., Etienne G., Liferman F., Neau D., et al. CD8+HLA-DR+ T lymphocytes are increased in common variable immunodeficiency patients with impaired memory B-cell differentiation. Clin Immunol 2006, 119:51-58.
53. Ko J., Radigan L., Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol 2005, 116:37-41.
54. Fischer M.B., Wolf H.M., Hauber I., Eggenbauer H., Thon V., Sasgary M., et al. Activation via the antigen receptor is impaired in T cells, but not in B cells from patients with common variable immunodeficiency. Eur J Immunol 1996, 26:231-237.
55. Borte S., Pan-Hammarström Q., Liu C., Sack U., Borte M., Wagner U., et al. Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood 2009, 114:4089-4098.
56. Nonoyama S., Farrington M., Ishida H., Howard M., Ochs H.D. Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin. J Clin Invest 1993, 92:1282-1287.
57. Capolunghi F., Cascioli S., Giorda E., Rosado M.M., Plebani A., Auriti C., et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 2008, 180:800-808.
58. Bayry J., Fournier E.M., Maddur M.S., Vani J., Wootla B., Sibéril S., et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011, 36:9-15.